Option chain shows key data for Korro Bio's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Korro Bio.

Korro Bio (NASDAQ:KRRO) Stock, Option Chain

KORRO BIO INC

Korro Bio

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.

Uber,Sign,On,Its,Headquarters,Building,In,San,Francisco,,California,

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

COHR

HLLY

KRRO

MCRB

PAYC

SONO

UBER

Uber To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday

Analyst,Works,On,Personal,Computer,Showing,Business,Analytics,Dashboard,With

Initiation

CGON

PCTY

TARA

URGN

This UroGen Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Stock market analysts

ALAB

ENGN

INGM

This TechnipFMC Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Korro Bio Inc

Press Releases

Korro to Participate in Upcoming Investor Conferences

Health Care

Management

CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors

Korro to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency and Provides Pipeline Update

Korro to Present at the TD Cowen 45th Annual Health Care Conference

KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency

Earnings

Korro Reports Full Year 2024 Financial Results and Provides Business Updates

Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer

Korro Reports First Quarter 2025 Financial Results and Provides Business Updates

CAMP

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Atossa Therapeutics

Cellectis S.A. - American Depositary Shares

Cellectis

CytomX Therapeutics

Editas Medicine

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharma

EXoZymes

Fate Therapeutics

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Lyell Immunopharma

Molecular Partners AG - American Depositary Shares

Molecular Partners

Nkarta

Puma Biotechnology

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences

TriSalus Life Sciences, Inc. - Common Stock

TriSalus Life Sciences

Tango Therapeutics

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Exagen

Chardan Capital

Oppenheimer

HC Wainwright & Co.

Cantor Fitzgerald

RBC Capital

Comments

Korro Bio

Korro Bio (KRRO) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell